29/03/2019 17:45:00

Award of Share Options

Summit Therapeutics plc 

(‘Summit’ or the ‘Company’)

Award of Share Options

Oxford, UK, and Cambridge, MA, US, 29 March 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces the annual grant of options over new ordinary shares of one penny nominal value (‘Ordinary Shares’) on 29 March 2019 to the Chief Executive Officer, PDMRs and other employees in line with the Company’s Long Term Incentive Plan.

Details of the grant to the Chief Executive Officer and the other PDMRs are summarised below.

Director/PDMRPositionOptions AwardedTotal number of Options Held
Glyn EdwardsChief Executive Officer3,000,0005,785,268
David RoblinChief Operating Officer, President of R&D2,000,0003,539,661
Daniel ElgerChief Commercial Officer1,500,0001,923,430

All options awarded to the Chief Executive Officer and the other PDMRs on 29 March 2019 have an exercise price of 27.5 pence per share and will vest in full on 29 March 2022 subject to achievement of performance conditions pertaining to corporate and programme development milestones and continued service to the Company.

In addition, the Company has granted Options over a further 4,896,000 Ordinary Shares to other employees of the Company on the same date. These options also have an exercise price of 27.5 pence per share. They will vest in nine equal tranches on a quarterly basis from 29 March 2020 and will vest in full on 29 March 2022, or sooner on the happening of certain corporate events reflecting the achievement of the Group’s long-term objectives.

The exercise price of 27.5 ­pence per share for all options granted was the mid-market closing price of the Ordinary Shares on AIM on 29 March 2019. The maximum number of outstanding share options following the grants referred to above is 20,418,951 representing approximately 12.7 ­­­per cent of the currently issued ordinary share capital of the Company.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit

 

 

Glyn Edwards / Richard Pye (UK office)

Tel:

44 (0)1235 443 951
Michelle Avery (US office)

 

+1 617 225 4455

 

 

 

Cairn Financial Advisers LLP (Nominated Adviser)

Tel:

+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson

 

 

-END-

Summit Master_rgb_png.png

Related content
12 Jun - 
Summit Therapeutics Reports Financial Results and Opera..
05 Jun - 
Notice of First Quarter Results
14 May - 
UK Annual Report and Notice of AGM
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
2
ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile

Related stock quotes


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 18:41:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB4 - 2019-06-16 19:41:26 - 2019-06-16 18:41:26 - 1000 - Website: OKAY